Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On Monday, BB&T Corporation ( BBT - Analyst Report ) announced the accomplishment of the purchase of Crump Group Inc.’s insurance business. BB&T, in particular, acquired the life and property and casualty insurance operating units of Crump. It, however, excluded Ascensus, the retirement services business of Crump.
BB&T shelled out $570 million in cash to complete the purchase. The acquisition is projected to be accretive to the company’s earnings. It is anticipated to enhance BB&T’s Insurance annual revenue by approximately $300 million. As a result of the deal closure, BB&T becomes the largest independent wholesale distributor of life insurance in the country.
The acquisition is a strategic fit as it would help BB&T in increasing its market share in life insurance distribution and P&C businesses. Moreover, we believe that the company’s top line will also get a boost as it was otherwise bogged down by several financial reform rules.
Our Take
BB&T has extensively depended on acquisitions to broaden its top line and market share. The company announced four acquisitions in 2011. With these acquisitions, the company has been able to extend its footprints in the California, Florida, Washington D.C. and Baltimore. These deals have also significantly added to BB&T’s branch network.
Moreover, after its deal to acquire BankAtlantic, a wholly owned subsidiary of BankAtlantic Bancorp Inc. ( BBX ) was opposed in the court, BB&T modified certain terms of the agreement. Apart from the earlier deal terms, BB&T will also assume BankAtlantic Bancorp’s obligations related to the outstanding trust preferred securities (TruPS) that have a balance of about $285 million.
For BB&T, the BankAtlantic transaction will enable it to boost its expansion strategy in the Florida region. Moreover, the deal will add 78 branches to the company’s 64-branch network in the Florida region. Besides, the substantial increase in BB&T’s market share and footprints following the acquisition would also improve its revenue stream over the medium term.
Therefore, even though the current tepid economic recovery coupled with regulatory issues remain an overhang on the stock, we believe BB&T’s growth strategies with focus on both organic as well as inorganic front will augur well going forward. In addition, its solid liquidity position and steady improvement in capital and profitability ratios would encourage investors to consider the company as a value investment.
BB&T shares maintain a Zacks #2 Rank, which translates into a short-term Buy recommendation. Considering the fundamentals we also have a long-term Outperform recommendation on the stock.
Read the full Analyst Report on BBT
Read the full on BBX